R&D

Overview

AGM-331 AGM-130 AGM-380 AGM-290 AGM-212 AGM-217 AGM-260
Solid cancer Drug AGM-331
AGM-330 which is comprised of branched peptides with multiple antigenic peptide system has the specific binding affinity of various cancer cells targeting nucleolin protein which is expressed with the plasma membrane of tumor cells.

  • Nucleolin targeting AGM-331 has great potential for use in cancer diagnosis and targeted drug delivery in cancer therapy.

  • AGM-330 has a specific and selective binding affinity (KD = 57.7 nM) to the nucleolin protein

  • Treatment with AGM-330-Paclitaxel conjugate (AGM-331) facilitates the specific localization of PTX in tumor tissues, resulting in improved anticancer efficacy in a xenograft model of breast cancer.